ニュース

Samsung Biologics, C&T Shares Volatile After Spin-Off Plan
Samsung Biologics Co. said it plans to carve its business into a contract drug manufacturer and a holding firm which will ...
Samsung Biologics splits biosimilar business to boost CDMO, investment flexibility
Samsung Biologics, the biotech arm of Samsung Group, announced Thursday that it will spin off its biosimilar operations into ...
Samsung BioLogics spin-off to separate contract drug making, new growth drivers
South Korean drug maker Samsung BioLogics said on Thursday it plans to split its business into contract manufacturing and development companies, to help allay customer concerns about conflicts of ...
Fierce Pharma1 日
CDMO Samsung Biologics telegraphs spinoff of biosim unit
In a bid to allay conflict-of-interest concerns, Korean manufacturing giant Samsung Biologics is decoupling from its ...
Yonhap News (English) on MSN1 日
Samsung Biologics plans to separate CDMO, biosimilar biz
Seoul: Samsung Biologics, a biotech arm of South Korea's Samsung Group, said on Thursday it plans to spin off its biosimilar ...
중앙일보2 日
Samsung Biologics to split into manufacturing and development units
Shares in Samsung Biologics rose 7.1 percent the previous day following reports of a possible spinoff and investor optimism about the move. Biologics counts tech giant Samsung Electronics and builder ...
kedglobal2 日
Samsung Biologics to spin off biosimilar unit Samsung Bioepis
Samsung Biologics Co., the world’s largest contract drugmaker, will undergo a strategic split to separate its contract development and manufacturing organization (CDMO) business from its biosimilar ...
Investing.com9 日
Samsung Biologics Co Ltd (207940)
Samsung Biologics (207940)の株価は今日はいくらですか？ Samsung Biologicsの株価は本日998,000.00です どの株式取引所でSamsung Biologics株は取引されていますか？ Samsung Biologicsは、ソウル証券取引所株式取引所に上場され、取引されています。 Samsung Biologicsの株式シンボル ...